Pipeline
The Science
About us
Investors
News

Hit enter to search or ESC to close

Chairman’s Address to Shareholders 2019 Annual General Meeting

November 26, 2019November 26, 2019 Alterity Therapeutics

Chairman’s Address to Shareholders 2019 AGM

Post navigation

AGM 2019 Presentation

European Commission approves Orphan Designation for Alterity’s lead drug candidate

Related Posts

ATH434 protects brain cells and improves motor function

April 21, 2021June 23, 2021

Prana meeting with investors at world’s largest healthcare conference in San Francisco

January 8, 2018

Alterity Therapeutics AAN Presentation 5 May 2019

May 6, 2019May 27, 2019

Leave a Reply Cancel reply

Your email address will not be published.Required fields are marked *

Save my name, email, and website in this browser for the next time I comment.

Δ

Recent Posts

Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program
Presentation of New Biomarker Data at Scientific Congress
XBRL 30 June 2021 filed with the SEC
Alterity Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer’s and Parkinson’s
Quarterly Cash Flow Report

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065